Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2006, p. 3548-3555, Vol. 50, No. 11
0066-4804/06/$08.00+0 doi:10.1128/AAC.00943-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Université Paris-Descartes, Faculté de Médecine,1 Assistance Publique-Hôpitaux de Paris,2 Pharmacologie Clinique,3 Gynécologie-Obstétrique 1,4 Groupe Hospitalier Cochin-Saint-Vincent de Paul,5 INSERM,6 Virologie,7 Unité d'Immunologie-Hématologie Pédiatrique,8 Groupe Hospitalier Necker-Enfants Malades,9 Centre René-Huguenin Saint-Cloud,10 EA3620, Paris, France,11
Received 25 July 2005/ Returned for modification 23 November 2005/ Accepted 10 August 2006
The pharmacokinetics of lopinavir were investigated by the use of a population approach performed with the nonlinear mixed effect modeling program NONMEM and 157 children ranging in age from 3 days to 18 years. The pharmacokinetics of lopinavir were well described by a one-compartment model in which the absorption and the elimination rate constants were equal. Typical population estimates of the apparent volume of distribution (V/F) and plasma clearance (CL/F) were 24.6 liters and 2.58 liters/h, respectively. The lopinavir V/F and CL/F were both related to body weight (BW), with an important increase in weight-normalized CL/F for the lowest BW. Combined treatment with lopinavir and nevirapine was found to increase the CL/F. The lopinavir CL/F was also age and sex related, as a 39% increase was observed after the age of 12 years for boys compared to the CL/F for girls. The consequences of these pharmacokinetic discrepancies and the necessity to modify the currently recommended dosage regimen should be further investigated.
Published ahead of print on 28 August 2006.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»